Hybrid Allosteric Receptor Stem Cells for Myocardial Infarction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current stem cell therapies for cardiovascular diseases, such as myocardial infarction, face challenges with inadequate homing and poor differentiation of stem cells, requiring prolonged culture periods and the use of various cytokines and growth factors, resulting in heterogeneous cell phenotypes.

Innovation Solution

Engineered stem cells expressing hybrid allosteric receptors (HAR) comprising a CXCR4 domain, BMP2RII domain, and ALK3 domain, which facilitate targeted migration and differentiation into cardiomyocytes upon binding with SDF-1α, enhancing cardiomyocyte differentiation and cytokine secretion.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional stem cell therapy is used for myocardial infarction treatment, then stem cells can be administered to patients, but the stem cells exhibit inadequate homing and poor differentiation capability

Engineering Contradiction:

Improvehoming and differentiation capabilityVSAvoiddifferentiation efficiency

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent merges the extracellular domain of CXCR4 (for SDF-1α binding and homing) with the intracellular signaling domains of BMP2RII and ALK3 (for cardiomyocyte differentiation) into a single hybrid allosteric receptor molecule. This unified receptor structure enables stem cells to simultaneously achieve targeted migration and efficient differentiation, resolving the contradiction between homing reliability and differentiation productivity

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The hybrid allosteric receptor performs multiple functions within a single molecular structure: it binds SDF-1α for homing guidance, transmits differentiation signals through BMP pathways, and coordinates both homing and differentiation processes. This multi-functionality eliminates the need for separate mechanisms and improves overall therapeutic efficiency

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Manufacturing precision

If prolonged culture periods are used to generate fully differentiated cells from hMSCs, then differentiation can be achieved, but the process becomes complex requiring various cytokines, growth factors, and transcription factors

Engineering Contradiction:

Improvedifferentiation accuracyVSAvoidculture process complexity

Core Design Contradiction:

Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent extracts and consolidates the essential differentiation signaling functions into the hybrid allosteric receptor's intracellular domains (BMP2RII and ALK3). By embedding these signaling capabilities directly in the receptor, the system eliminates the need for external cytokines, growth factors, and transcription factors that would otherwise be required in complex culture conditions

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The hybrid allosteric receptor enables stem cells to autonomously receive differentiation signals through SDF-1α binding and internally process the signaling through BMP pathways. This self-service mechanism allows differentiation to occur without requiring complex external culture conditions or multiple added factors, simplifying the overall process while maintaining precision

Inventive Principle:

Principle #25Self-service

3Productivity

If traditional stem cell culture methods are used, then stem cells can be expanded, but the resulting cells are heterogeneous in phenotypical characteristics

Engineering Contradiction:

Improvecell expansion capabilityVSAvoidphenotypical homogeneity

Core Design Contradiction:

ProductivityVSManufacturing precision

Solution Approach 1:

The patent changes the key parameter of cell differentiation by introducing the hybrid allosteric receptor that responds to SDF-1α. This parameter change directs stem cells along a specific cardiomyocyte differentiation pathway, ensuring that expanded cells maintain phenotypical homogeneity rather than becoming heterogeneous through uncontrolled differentiation

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The HAR-engineered stem cells demonstrate improved cardiomyocyte differentiation and functional improvements in acute myocardial infarction models, offering a promising treatment for cardiovascular diseases by enhancing cell homing and differentiation efficiency.

Implementation Method 1

The binding of SDF-1α to CXCR4 activates the co-stimulatory signals, bone morphogenetic protein 2 type II receptor (BMP2R2) and BMP type I receptor (ALK3), to induce differentiation into cardiomyocytes

Methodology Applied

Scientific EffectReceptor-ligand binding:

Data Source

PatentUS20230302135A1Hybrid allosteric receptor-engineered stem cells

Publication Date: 2023.09.28 THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA

AI summary

Described herein are mesenchymal stem cells (MCS) expressing hybrid allosteric receptors (HAR) that are responsive to stromal cell-derived factor 1 alpha (SDF-1α) secreted from acutely infarcted myocardium. Binding of SDF-1α to CXCR4 activates the co-stimulatory signals, bone morphogenetic protein 2 type II receptor (BMP2R2) and BMP type I receptor (ALK3), in order to accelerate the differentiation into cardiomyocytes. HAR-MSC CXCR4 differentiates into cardiomyocytes through Smad1/5 phosphorylation induced by the BMP2 signaling. In acute myocardial infarction (AMI) models, HAR-MSC CXCR4 treatment leads to the functional improvements by facilitated differentiation and increased cytokine secretion. HAR-MSC CXCR4 cells can be used for the treatment of AMI.